U.K. Antitrust Watchdog's Acceptance of Vifor Offer Is Eye-Catching -- Market Talk

Dow Jones12-11

1712 GMT - The U.K. Competition and Markets Authority's acceptance of Swiss pharmaceutical company Vifor's offer to pay the National Health Service 23 million pounds to end an investigation is eye-catching, Tom Smith, a partner at law firm Geradin Partners, says in a LinkedIn post. The CMA can only accept commitments to address competition concerns it has identified, he says, but adds that the CMA stated explicitly that it didn't find the NHS was misled by claims Vifor made about a rival's intravenous iron treatment. "The CMA is therefore not alleging any effects, but basing the compensation on those effects," he says. "The CMA only ever does this type of thing where the NHS is the victim." (edith.hancock@wsj.com)

(END) Dow Jones Newswires

December 10, 2024 12:14 ET (17:14 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490395046?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-11 01:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490395046","market":"sg","top_or_hot":-1,"title":"U.K. Antitrust Watchdog's Acceptance of Vifor Offer Is Eye-Catching -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1712 GMT - The U.K. Competition and Markets Authority's acceptance of Swiss pharmaceutical company Vifor's offer to pay the National Health Service 23 million pounds to end an investigation is eye-catching, Tom Smith, a partner at law firm Geradin Partners, says in a LinkedIn post. The CMA can only accept commitments to address competition concerns it has identified, he says, but adds that the CMA stated explicitly that it didn't find the NHS was misled by claims Vifor made about a rival's intravenous iron treatment. \"The CMA is therefore not alleging any effects, but basing the compensation on those effects,\" he says. \"The CMA only ever does this type of thing where the NHS is the victim.\" (edith.hancock@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 10, 2024 12:14 ET (17:14 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.K. Antitrust Watchdog's Acceptance of Vifor Offer Is Eye-Catching -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.K. Antitrust Watchdog's Acceptance of Vifor Offer Is Eye-Catching -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 01:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1712 GMT - The U.K. Competition and Markets Authority's acceptance of Swiss pharmaceutical company Vifor's offer to pay the National Health Service 23 million pounds to end an investigation is eye-...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMA","symbol_name":"联信银行","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2490395046","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490395046","pubTimestamp":1733850840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1712 GMT - The U.K. Competition and Markets Authority's acceptance of Swiss pharmaceutical company Vifor's offer to pay the National Health Service 23 million pounds to end an investigation is eye-catching, Tom Smith, a partner at law firm Geradin Partners, says in a LinkedIn post. The CMA can only accept commitments to address competition concerns it has identified, he says, but adds that the CMA stated explicitly that it didn't find the NHS was misled by claims Vifor made about a rival's intravenous iron treatment. \"The CMA is therefore not alleging any effects, but basing the compensation on those effects,\" he says. \"The CMA only ever does this type of thing where the NHS is the victim.\" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMA":"联信银行","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4211":"区域性银行","BK4207":"综合性银行","BK4589":"SVB概念"},"translate_title":"英国反垄断监管机构接受Vifor要约引人注目——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMA":0.72},"content_text":"1712 GMT - The U.K. Competition and Markets Authority's acceptance of Swiss pharmaceutical company Vifor's offer to pay the National Health Service 23 million pounds to end an investigation is eye-catching, Tom Smith, a partner at law firm Geradin Partners, says in a LinkedIn post. The CMA can only accept commitments to address competition concerns it has identified, he says, but adds that the CMA stated explicitly that it didn't find the NHS was misled by claims Vifor made about a rival's intravenous iron treatment. \"The CMA is therefore not alleging any effects, but basing the compensation on those effects,\" he says. \"The CMA only ever does this type of thing where the NHS is the victim.\" (edith.hancock@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2024 12:14 ET (17:14 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490395046"}